Amgen Reports on Actions Against Modern Slavery
Biotechnology company Amgen has published a statement in accordance with the UK's Modern Slavery Act 2015. The report outlines the company's measures to prevent human trafficking and forced labor within its supply chain.
Biotechnology firm Amgen has issued a public statement detailing its compliance with the UK's Modern Slavery Act 2015. The statement outlines the company's policies and procedures aimed at preventing modern slavery and human trafficking throughout its global supply chain.
Amgen Ltd., a subsidiary, provides clinical development support and conducts sales and marketing activities in the UK. The company's medicines are primarily manufactured at Amgen facilities in the US, Puerto Rico, and Ireland. Amgen acknowledges its role as a consumer of various goods and services, emphasizing the importance of supply chain oversight.
Corporate policies, including a Supplier Code of Conduct, explicitly prohibit forced labor and human trafficking. Amgen mandates that suppliers uphold human rights, prohibit child labor, and refrain from physical or mental coercion. Amgen employees are also bound by a Staff Code of Conduct and receive mandatory annual training.
The company conducts risk assessments and requires suppliers to adhere to ethical practices. In 2017, Amgen implemented a Supplier Sustainability Assessment to evaluate key suppliers' performance, including labor practices, with assessments conducted by an independent third party.
Amgen monitors the effectiveness of its efforts through key performance indicators such as the number of assessed suppliers, GMP suppliers passing risk assessments, and employee training completion rates. The company maintains that continuous risk assessment and training are crucial for managing modern slavery risks.